Tenaya Therapeutics, Inc.

Stage 4 · Declining · week 12

As of Oct 22, 2026, Tenaya Therapeutics is in Stage 4, the downtrend phase, now in week 12 (since Aug 4, 2026). It closed at $0.39, 77.2% below its 52-week high and below its 200-day average, which is falling.

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. More about the company

$0.39

-4.53% today

$87.0M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is TNYA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 14w

S4 18w

S4 24w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S3 5w → S4 14w → S1 8w → S2 8w → S3 12w → S4 18w → S1 6w → S4 24w → S1 12w → S2 12w → S3 7w → S4 8w → S1 3w → S4 3w → S1 5w → S4 2w → S1 6w → S4 11w current

Total tracked: 165 weeks across 18 stage runs.

TNYA among Biotechnology458th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…458	TNYATenaya Therapeutics, Inc.	Stage 4 · wk 12	12	−41.3%

vs 52W High

-77.2%

$0.38 lo$1.70 hi

77.2% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 12

1w13w26w

Week 12, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-46.2%

200 DMA: $0.72 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.58x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-41.3%

-49.9%

-43.3%

YTD

-47.2%

-78.8%

Scan Membership

Breakout Watch

Latest: 2024-02-28

2 appearances in last 60 days. First seen: 2023-05-01.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 12 · Vol 0.58x

2026-10-21S4

Wk 12 · Vol 0.73x

2026-10-20S4

Wk 11 · Vol 1.12x

2026-10-19S4

Wk 11 · Vol 1.04x

2026-10-16S4

Wk 11 · Vol 2.43x

2026-10-15S4

Wk 11 · Vol 1.80x

2026-10-14S4

Wk 11 · Vol 7.39x

2026-10-13S4

Wk 10 · Vol 1.05x

2026-10-12S4

Wk 10 · Vol 1.03x

2026-10-09S4

Wk 10 · Vol 1.80x

2026-10-08S4

Wk 10 · Vol 1.55x

2026-10-07S4

Wk 10 · Vol 1.62x

Moving averages & range

50 DMA

$0.61

200 DMA

$0.72

52W High

$1.70

52W Low

$0.38

5D Low

$0.38

Resistance levels (recent highs)

20d High

$0.61

60d High

$0.79

120d High

$1.00

250d High

$1.66

Next resistance

+57.2%

to 20d High

ROE

-121.9%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 1.3

Tenaya Therapeutics: quick answers

What stage is Tenaya Therapeutics in?

As of Oct 22, 2026, Tenaya Therapeutics (TNYA) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 4, 2026 and is in week 12. What the four stages mean

Is Tenaya Therapeutics in an uptrend?

No. Tenaya Therapeutics is in a Stage 4 downtrend. It trades 46.2% below its 200-day average, which is falling.

How far is Tenaya Therapeutics from its 52-week high?

Tenaya Therapeutics closed at $0.39 on Oct 22, 2026, 77.2% below its 52-week high of $1.70. Its 52-week low is $0.38.

How has Tenaya Therapeutics performed over the past year?

As of Oct 22, 2026, Tenaya Therapeutics is down 78.8% over the past year and down 47.2% so far in 2026.

Which sector and industry is Tenaya Therapeutics in?

Tenaya Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.